You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 12, December 2004 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Diabetic Retinopathy
 •Macular Disorders
 •Alert me on articles by topic

Vitreous Levels of Vascular Endothelial Growth Factor and Stromal-Derived Factor 1 in Patients With Diabetic Retinopathy and Cystoid Macular Edema Before and After Intraocular Injection of Triamcinolone

H. Logan Brooks, Jr, MD; Sergio Caballero, Jr, MS; Charles K. Newell, MD; Robert L. Steinmetz, MD; Debbie Watson, BS, CRA; Mark S. Segal, MD, PhD; Jeffrey K. Harrison, PhD; Edward W. Scott, PhD; Maria B. Grant, MD

Arch Ophthalmol. 2004;122:1801-1807.

Background  Diffuse macular edema (DME) and/or aberrant neovascularization (NV) can cause vision loss in diabetic retinopathy (DR) and may be modulated by growth factors and chemokines. The chemokine stromal-derived factor 1 (SDF-1) is a potent stimulator of vascular endothelial growth factor (VEGF) expression, the main effector of NV, and the key inducer of vascular permeability associated with DME. Circulating endothelial cell precursors migrating in response to SDF-1 participate in NV.

Objective  To investigate the relationship between SDF-1 and (VEGF) in vitreous of patients with varying degrees of DR and DME before and after intraocular injection of triamcinolone acetonide, used to treat refractory DME.

Methods  In this prospective study, 36 patients were included and observed for 6 months. Vitreous VEGF and SDF-1 levels were measured by enzyme-linked immunosorbent assay in samples obtained immediately before and 1 month after injection of triamcinolone.

Results  Both VEGF and SDF-1 were significantly higher (P<.01) in patients with proliferative DR than in patients with nonproliferative DR. Levels of SDF-1 were markedly increased in patients with DME compared with those without DME. Vascular endothelial growth factor correlated with SDF-1 levels and disease severity (r2 = 0.88).

Conclusions  Triamcinolone administration resulted in dramatic reductions of VEGF and SDF-1 to nearly undetectable levels, eliminated DME, and caused regression of active NV. Our results support a role for SDF-1 and VEGF in the pathogenesis of the adverse visual consequences of DR and suggest that the elimination of DME with regression and/or initiation of fibrosis of NV after triamcinolone injection may be due to the suppression of VEGF and SDF-1.


Author Affiliations: Southern Vitreoretinal Association, Tallahassee, Fla (Drs Brooks, Newell, and Steinmetz and Ms Watson); and the Departments of Pharmacology and Therapeutics (Mr Caballero and Drs Harrison and Grant), Medicine (Dr Segal), and Molecular Biology (Dr Scott), University of Florida, Gainesville.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stromal Cell-Derived Factor-1{alpha} Promotes Neuroprotection, Angiogenesis, and Mobilization/Homing of Bone Marrow-Derived Cells in Stroke Rats
Shyu et al.
J. Pharmacol. Exp. Ther. 2008;324:834-849.
ABSTRACT | FULL TEXT  

Early Effects of Triamcinolone on Vascular Endothelial Growth Factor and Endostatin in Human Choroidal Neovascularization
Tatar et al.
Arch Ophthalmol 2008;126:193-199.
ABSTRACT | FULL TEXT  

The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization
Lima e Silva et al.
FASEB J. 2007;21:3219-3230.
ABSTRACT | FULL TEXT  

Positive Feedback Regulation between MMP-9 and VEGF in Human RPE Cells
Hollborn et al.
IOVS 2007;48:4360-4367.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide Inhibits IL-6- and VEGF-Induced Angiogenesis Downstream of the IL-6 and VEGF Receptors
Ebrahem et al.
IOVS 2006;47:4935-4941.
ABSTRACT | FULL TEXT  

Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy.
Bandello et al.
Arch Ophthalmol 2006;124:643-650.
ABSTRACT | FULL TEXT  

Nitric Oxide Cytoskeletal-Induced Alterations Reverse the Endothelial Progenitor Cell Migratory Defect Associated With Diabetes
Segal et al.
Diabetes 2006;55:102-109.
ABSTRACT | FULL TEXT  

The Glucocorticoid Triamcinolone Acetonide Inhibits Osmotic Swelling of Retinal Glial Cells via Stimulation of Endogenous Adenosine Signaling
Uckermann et al.
J. Pharmacol. Exp. Ther. 2005;315:1036-1045.
ABSTRACT | FULL TEXT  

Triamcinolone Acetonide Destabilizes VEGF mRNA in Muller Cells under Continuous Cobalt Stimulation
Sears and Hoppe
IOVS 2005;46:4336-4341.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2004 American Medical Association. All Rights Reserved.